Mittelkettige Triglyceride und deren Einsatz in der
                    Ernährungsmedizin

Christina Heidt; Mary Newport; Ulrike Kämmerer

doi:10.1055/a-2401-5260

Aktuelle Ernährungsmedizin, Inhaltsverzeichnis

Aktuelle Ernährungsmedizin 2025; 50(04): 292-308
DOI: 10.1055/a-2401-5260

CME-Fortbildung

Mittelkettige Triglyceride und deren Einsatz in der Ernährungsmedizin

Christina Heidt

¹Hochschule Trier, Fachrichtung Lebensmitteltechnik, Hauptcampus Schneidershof, Trier, Deutschland

,

Mary Newport

²Spring Hill Neonatology, Inc., Spring Hill, FL, USA

,

Ulrike Kämmerer

³Universitätsklinikum Würzburg, Frauenklinik, Würzburg, Deutschland

› Institutsangaben

Abstract

Mittelkettige Triglyceride (MCT) sind Glycerinester von gesättigten Fettsäuren mittlerer Kettenlänge (C6:0–C12:0). Sie unterscheiden sich grundlegend von den üblichen langkettigen Fettsäuren in Nahrungsfetten sowohl in ihren biochemischen und physikalischen Eigenschaften als auch hinsichtlich Resorption, Transportmechanismus und zellulärem Metabolismus. Aufgrund dieser Unterschiede haben MCT einen wichtigen Stellenwert in der Ernährungsmedizin. Trotz der hohen Bekanntheit von MCT im Bereich der klinischen Ernährungstherapie, existieren zahlreiche Forschungslücken. Zudem werden immer neue Indikationsgebiete für die Verwendung von MCT entdeckt. Der Artikel gibt eine breite Übersicht zu MCT, ausgewählten Anwendungsgebieten und aktuellen Forschungsthemen.

Abstract

Medium-chain triglycerides (MCTs) are glycerol esters of saturated fatty acids with medium chain lengths. MCTs fundamentally differ from regular dietary fats in their biochemical and physical properties, as well as in terms of absorption, transport mechanisms, and cellular metabolism. Due to these differences, MCTs hold significant importance in nutritional medicine. Despite the high recognition of MCTs in the field of clinical nutrition therapy, numerous research gaps still exist. Furthermore, new indications for the use of MCTs are continually being discovered. This article provides a comprehensive overview of MCTs, selected applications, and current research topics.

Schlüsselwörter

MCT - LCT - KET - Epilepsie - Alzheimer

Keywords

MCT - LCT - KET - Epilepsy - Alzheimer's disease

Volltext

Referenzen

Literatur
1 Watanabe S, Tsujino S. Applications of Medium-Chain Triglycerides in Foods. Front Nutr 2022; 9: 802805
2 Penhaligan J, Poppitt SD, Miles-Chan JL. The Role of Bovine and Non-Bovine Milk in Cardiometabolic Health: Should We Raise the „Baa“?. Nutrients 2022; 14
3 Hartmann BM, Schmidt C, Sandfuchs K. Bundeslebensmittelschlüssel (BLS). Version 3.02. Karlsruhe: Max Rubner-Institut – Bundesforschungsinstitut für Ernährung und Lebensmittel 2014
4 Siener R, Ehrhardt C, Bitterlich N. et al. Effect of a fat spread enriched with medium-chain triacylglycerols and a special fatty acid-micronutrient combination on cardiometabolic risk factors in overweight patients with diabetes. Nutr Metab (Lond) 2011; 8: 21
5 Bloch R, Haberich FJ. Medium chain fatty acids. Absorption, metabolism and clinical significance. Dtsch Med Wochenschr 1973; 98: 20-25
6 Hashim SA, Arteaga A, Van Itallie TB. Effect of a saturated medium-chain triglyceride on serum-lipids in man. Lancet 1960; 1: 1105-1108
7 Jadhav HB, Annapure US. Triglycerides of medium-chain fatty acids: a concise review. J Food Sci Technol 2023; 60: 2143-2152
8 Lee YY, Tang TK, Chan ES. et al. Medium chain triglyceride and medium-and long chain triglyceride: metabolism, production, health impacts and its applications – a review. Crit Rev Food Sci Nutr 2022; 62: 4169-4185
9 Łoś-Rycharska E, Kieraszewicz Z, Czerwionka-Szaflarska M. Medium chain triglycerides (MCT) formulas in paediatric and allergological practice. Prz Gastroenterol 2016; 11: 226-231
10 Augustin K, Khabbush A, Williams S. et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol 2018; 17: 84-93
11 Han FY, Conboy-Schmidt L, Rybachuk G. et al. Dietary medium chain triglycerides for management of epilepsy: New data from human, dog, and rodent studies. Epilepsia 2021; 62: 1790-1806
12 Shcherbakova K, Schwarz A, Apryatin S. et al. Supplementation of Regular Diet With Medium-Chain Triglycerides for Procognitive Effects: A Narrative Review. Front Nutr 2022; 9: 934497
13 Schönfeld P, Wojtczak L. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res 2016; 57: 943-954
14 Roopashree P, Shetty SS, Kumari NS. Effect of medium chain fatty acid in human health and disease. Journal of Functional Foods 2021; 87: 104724
15 Shah ND, Limketkai BN. The use of medium-chain triglycerides in gastrointestinal disorders. Practical Gastroenterology 2017; 160: 20-25
16 Van Calcar SC, Sowa M, Rohr F. et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach. Mol Genet Metab 2020; 131: 23-37
17 Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr 1982; 36: 950-962
18 Omer E, Chiodi C. Fat digestion and absorption: Normal physiology and pathophysiology of malabsorption, including diagnostic testing. Nutr Clin Pract 2024; 39: S6-s16
19 Pepino MY, Kuda O, Samovski D. et al. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr 2014; 34: 281-303
20 Thompson G. Fat absorption and metabolism. Gastroenterol Jpn 1984; 19: 251-259
21 Heidt C, Wimmer K. Mittelkettige Triglyceride und deren Ensatz in der pädiatrischen Gastroenterologie und Hepatologie. Ernährungs Umschau 2024; 71
22 Nakamura K, Hagihara K, Nagai N. et al. Ketogenic effects of medium chain triglycerides containing formula and its correlation to breath acetone in healthy volunteers: a randomized, double-blinded, placebo-controlled, single dose-response study. Front Nutr 2023; 10: 1224740
23 Heidt C, Fobker M, Newport M. et al. Beta-Hydroxybutyrate (BHB), Glucose, Insulin, Octanoate (C8), and Decanoate (C10) Responses to a Medium-Chain Triglyceride (MCT) Oil with and without Glucose: A Single-Center Study in Healthy Adults. Nutrients 2023; 15
24 Takeuchi H, Sekine S, Kojima K. et al. The application of medium-chain fatty acids: edible oil with a suppressing effect on body fat accumulation. Asia Pac J Clin Nutr 2008; 17: 320-323
25 Traul KA, Driedger A, Ingle DL. et al. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000; 38: 79-98
26 Mason E, Hindmarch CCT, Dunham-Snary KJ. Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment. Endocrinol. Diabetes Metab 2023; 6: e385
27 Karunanidhi A, Basu S, Zhao XJ. et al. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2023; 140: 107689
28 Wood TR, Kelly C. Insulin, glucose and beta-hydroxybutyrate responses to a medium-chain triglyceride-based sports supplement: A pilot study. Journal of Insulin Resistance 2017; 2: 1-9
29 Lin TY, Liu HW, Hung TM. The Ketogenic Effect of Medium-Chain Triacylglycerides. Front Nutr 2021; 8: 747284
30 Grothues D, Engelhardt H, Genzel-Boroviczeny O. et al. S2k Leitlinie Cholestase im Neugeborenenalter. AWMF-Register Nr. 068/015 2020
31 Beyer G, Hoffmeister A, Michl P. et al. S3-leitlinie pankreatitis–leitlinie der deutschen gesellschaft für gastroenterologie, verdauungs-und stoffwechselkrankheiten (DGVS)–september 2021–AWMF registernummer 021-003. Zeitschrift für Gastroenterologie 2022; 60: 419-521
32 Hammermann J, Claßen M, Schmidt S. et al. S3-Leitlinie: Mukoviszidose bei Kindern in den ersten beiden Lebensjahren, Diagnostik und Therapie. AWMF online. 2020: 026-024
33 Lamprecht G, Pape U-F, Witte M. et al. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin e. V. in Zusammenarbeit mit der AKE, der GESKES und der DGVS. Aktuelle Ernährungsmedizin 2014; 39: e57-e71
34 Deutsche Gesellschaft für Lymphologie und Gesellschaft Deutschsprachiger Lymphologen (2017) S2k Leitlinie „Diagnostik und Therapie des Lymphödems“. AWMF Reg.-Nr.058-001 M
35 Mutschler F, Wimmer K. Ernährung bei Kindern mit cholestatischen Lebererkrankungen. Kinder- und Jugendmedizin 2022; 22: 450-460
36 Diéguez-Castillo C, Jiménez-Luna C, Prados J. et al. State of the Art in Exocrine Pancreatic Insufficiency. Medicina (Kaunas) 2020; 56
37 Campbell I, Campbell H. Mechanisms of insulin resistance, mitochondrial dysfunction and the action of the ketogenic diet in bipolar disorder. Focus on the PI3K/AKT/HIF1-a pathway. Med Hypotheses 2020; 145: 110299
38 Wiemer-Kruel A. Ketogene Ernährungstherapie. Monatsschrift Kinderheilkunde 2024; 1-6
39 Kossoff EH, Zupec-Kania BA, Auvin S. et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018; 3: 175-192
40 Barzegar M, Afghan M, Tarmahi V. et al. Ketogenic diet: overview, types, and possible anti-seizure mechanisms. Nutr Neurosci 2021; 24: 307-316
41 Eleti S. Drugs in Alzheimer's disease Dementia: An overview of current pharmacological management and future directions. Psychiatr Danub 2016; 28: 136-140
42 Espay AJ, Sturchio A, Schneider LS. et al. Soluble Amyloid-β Consumption in Alzheimer's Disease. J Alzheimers Dis 2021; 82: 1403-1415
43 Cunnane S, Nugent S, Roy M. et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 2011; 27: 3-20
44 Mosconi L, Brys M, Glodzik-Sobanska L. et al. Early detection of Alzheimer’s disease using neuroimaging. Exp Gerontol 2007; 42: 129-138
45 Leybaert L, De Bock M, Van Moorhem M. et al. Neurobarrier coupling in the brain: adjusting glucose entry with demand. J Neurosci Res 2007; 85: 3213-3220
46 Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol 2013; 719: 170-179
47 An Y, Varma VR, Varma S. et al. Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimers Dement 2018; 14: 318-329
48 Cunnane SC, Courchesne-Loyer A, Vandenberghe C. et al. Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease. Front Mol Neurosci 2016; 9: 53
49 Owen OE, Morgan AP, Kemp HG. et al. Brain metabolism during fasting. J Clin Invest 1967; 46: 1589-1595
50 Croteau E, Castellano CA, Fortier M. et al. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Exp Gerontol 2018; 107: 18-26
51 Yin JX, Maalouf M, Han P. et al. Ketones block amyloid entry and improve cognition in an Alzheimer’s model. Neurobiol Aging 2016; 39: 25-37
52 Youm YH, Nguyen KY, Grant RW. et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21: 263-269
53 Xu Y, Zheng F, Zhong Q. et al. Ketogenic Diet as a Promising Non-Drug Intervention for Alzheimer's Disease: Mechanisms and Clinical Implications. J Alzheimers Dis 2023; 92: 1173-1198
54 Shippy DC, Wilhelm C, Viharkumar PA. et al. β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology. J Neuroinflammation 2020; 17: 280
55 Cunnane SC, Trushina E, Morland C. et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov 2020; 19: 609-633
56 Chung JY, Kim OY, Song J. Role of ketone bodies in diabetes-induced dementia: sirtuins, insulin resistance, synaptic plasticity, mitochondrial dysfunction, and neurotransmitter. Nutr Rev 2022; 80: 774-785
57 Hernandez AR, Hernandez CM, Truckenbrod LM. et al. Age and Ketogenic Diet Have Dissociable Effects on Synapse-Related Gene Expression Between Hippocampal Subregions. Front Aging Neurosci 2019; 11: 239
58 Andersen JV, Westi EW, Neal ES. et al. β-Hydroxybutyrate and Medium-Chain Fatty Acids are Metabolized by Different Cell Types in Mouse Cerebral Cortex Slices. Neurochem Res 2023; 48: 54-61
59 Meer N, Fischer T. Medium-Chain Triglycerides (MCTs) for the Symptomatic Treatment of Dementia-Related Diseases: A Systematic Review. J Nutr Metab 2024; 2024: 9672969
60 Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc 1995; 95: 693-697
61 Nebeling LC, Miraldi F, Shurin SB. et al. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995; 14: 202-208
62 Khodabakhshi A, Akbari ME, Mirzaei HR. et al. Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clin Nutr 2021; 40: 751-758
63 Hagihara K, Kajimoto K, Osaga S. et al. Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer. Nutrients 2020; 12
64 Egashira R, Matsunaga M, Miyake A. et al. Long-Term Effects of a Ketogenic Diet for Cancer. Nutrients 2023; 15
65 Mori T, Ohmori H, Luo Y. et al. Giving combined medium-chain fatty acids and glucose protects against cancer-associated skeletal muscle atrophy. Cancer Sci 2019; 110: 3391-3399
66 Santos HO, Howell S, Earnest CP. et al. Coconut oil intake and its effects on the cardiometabolic profile – A structured literature review. Prog Cardiovasc Dis 2019; 62: 436-443
67 Wallace TC. Health Effects of Coconut Oil – A Narrative Review of Current Evidence. J Am Coll Nutr 2019; 38: 97-107
68 Takaoka T, Yaegashi A, Watanabe D. Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis. Adv Nutr 2024; 15: 100282
69 Ryan AM, Prado CM, Sullivan ES. et al. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 2019; 67-68: 110539
70 Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol 2010; 26: 146-151
71 Schmidt SF, Rohm M, Herzig S. et al. Cancer Cachexia: More Than Skeletal Muscle Wasting. Trends Cancer 2018; 4: 849-860
72 Roopashree PG, Shetty SS, Shetty VV. et al. Inhibitory effects of medium-chain fatty acids on the proliferation of human breast cancer cells via suppression of Akt/mTOR pathway and modulating the Bcl-2 family protein. J Cell Biochem 2024; doi:10.1002/jcb.30571
73 Sheela DL, Narayanankutty A, Nazeem PA. et al. Lauric acid induce cell death in colon cancer cells mediated by the epidermal growth factor receptor downregulation: An in silico and in vitro study. Hum Exp Toxicol 2019; 38: 753-761
74 Narayanan A, Baskaran SA, Amalaradjou MA. et al. Anticarcinogenic properties of medium chain fatty acids on human colorectal, skin and breast cancer cells in vitro. Int J Mol Sci 2015; 16: 5014-5027
75 Lappano R, Sebastiani A, Cirillo F. et al. The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discov 2017; 3: 17063
76 Fauser JK, Matthews GM, Cummins AG. et al. Induction of apoptosis by the medium-chain length fatty acid lauric acid in colon cancer cells due to induction of oxidative stress. Chemotherapy 2013; 59: 214-224
77 Wang H, Shao Z, Xu Z. et al. Antiproliferative and apoptotic activity of gemcitabine-lauric acid conjugate on human bladder cancer cells. Iran J Basic Med Sci 2022; 25: 536-542
78 Takagi T, Fujiwara-Tani R, Mori S. et al. Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2023; 24
79 Cohen LA, Thompson DO. The influence of dietary medium chain triglycerides on rat mammary tumor development. Lipids 1987; 22: 455-461
80 Ling PR, Istfan NW, Lopes SM. et al. Structured lipid made from fish oil and medium-chain triglycerides alters tumor and host metabolism in Yoshida-sarcoma-bearing rats. Am J Clin Nutr 1991; 53: 1177-1184
81 Ohkawa A, Sato N, Hatakeyama K. Effect of medium-chain triglyceride emulsion in total parenteral nutrition on experimental hepatic metastasis in the rat. JPEN J Parenter Enteral Nutr 1997; 21: 220-223
82 Spiekerkoetter U, Lindner M, Santer R. et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 2009; 32: 498-505
83 Bhattacharya K. Investigation and management of the hepatic glycogen storage diseases. Transl Pediatr 2015; 4: 240-248
84 Rossi A, Hoogeveen IJ, Bastek VB. et al. Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations. J Inherit Metab Dis 2020; 43: 770-777
85 Parhofer KG. Update lipidology : Evidence-based treatment of dyslipidemia. Inn Med (Heidelb) 2023; 64: 611-621
86 Wakabayashi T, Takahashi M, Okazaki H. et al. Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1. J Atheroscler Thromb 2024; 31: 1005-1023
87 Baertling F, Mayatepek E, Thimm E. et al. Malonic aciduria: long-term follow-up of new patients detected by newborn screening. Eur J Pediatr 2014; 173: 1719-1722
88 Kanabus M, Fassone E, Hughes SD. et al. The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis 2016; 39: 415-426
89 Embleton ND, Jennifer Moltu S, Lapillonne A. et al. Enteral Nutrition in Preterm Infants (2022): A Position Paper From the ESPGHAN Committee on Nutrition and Invited Experts. J Pediatr Gastroenterol Nutr 2023; 76: 248-268